What is the price target for PSTV stock?
11 analysts have analysed PSTV and the average price target is 6.02 USD. This implies a price increase of 2208.4% is expected in the next year compared to the current price of 0.2607.
NASDAQ:PSTV • US72941H5090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PLUS THERAPEUTICS INC (PSTV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-11-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-31 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-09-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-03 | D. Boral Capital | Upgrade | Hold -> Buy |
| 2025-08-18 | Maxim Group | Maintains | Buy -> Buy |
| 2025-06-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-25 | D. Boral Capital | Maintains | Hold -> Hold |
| 2025-06-05 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-05-05 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-03-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-17 | D. Boral Capital | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 220K | 4.913M 2,133.18% | 5.824M 18.54% | 5.43M -6.77% | 7.944M 46.30% | 23.892M 200.76% | 47.297M 97.96% | 135.29M 186.04% | 187.93M 38.91% | 336.7M 79.16% | 754.94M 124.22% | 1.117B 47.96% | |
| EBITDA YoY % growth | -19.09M -62.19% | -12.693M 33.51% | -13.972M -10.08% | -12.24M 12.40% | -15.096M -23.33% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -19.71M -61.96% | -13.321M 32.42% | -14.695M -10.31% | -15.445M -5.10% | -22.985M -48.82% | -15.749M 31.48% | -6.556M 58.38% | 58.083M 986.01% | 97.595M 68.03% | 212.76M 118.00% | 564.83M 165.48% | 875.94M 55.08% | |
| Operating Margin | -8,959.09% | -271.14% | -252.32% | -284.44% | -289.34% | -65.92% | -13.86% | 42.93% | 51.93% | 63.19% | 74.82% | 78.42% | |
| EPS YoY % growth | -9.75 42.48% | -4.53 53.54% | -2.17 52.10% | -0.25 88.56% | -0.17 31.16% | -0.09 44.78% | -0.05 45.95% | 0.19 480.00% | 0.35 78.95% | 0.84 141.18% | 1.96 134.15% | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.03 93.23% | -0.03 97.14% | -0.04 -304.00% | -0.04 -2.00% | -0.04 -23.08% | -0.03 9.99% | -0.03 25.00% | -0.03 25.00% | -0.03 25.00% |
| Revenue Q2Q % growth | 1.311M -7.15% | 1.403M 32.48% | 1.814M 30.50% | 2.151M 53.97% | 2.36M 80.02% | 5.28M 276.34% | 5.509M 203.69% | 5.968M 177.45% | 6.198M 162.63% |
| EBITDA Q2Q % growth | -3.264M -2.64% | -3.774M -11.33% | -3.774M -187.00% | -3.774M 9.76% | -3.774M -15.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.36M -11.79% | -4.651M -31.53% | -5.476M -256.07% | -5.831M -30.11% | -5.96M -36.69% | -4.216M 9.36% | -4.398M 19.69% | -4.765M 18.28% | -4.948M 16.98% |
All data in USD
11 analysts have analysed PSTV and the average price target is 6.02 USD. This implies a price increase of 2208.4% is expected in the next year compared to the current price of 0.2607.
PLUS THERAPEUTICS INC (PSTV) will report earnings on 2026-03-25, after the market close.
The consensus EPS estimate for the next earnings of PLUS THERAPEUTICS INC (PSTV) is -0.03 USD and the consensus revenue estimate is 1.31M USD.
The number of analysts covering PLUS THERAPEUTICS INC (PSTV) is 11.